Literature DB >> 8777990

Bradykinin enhances GLUT4 translocation through the increase of insulin receptor tyrosine kinase in primary adipocytes: evidence that bradykinin stimulates the insulin signalling pathway.

S Isami1, H Kishikawa, E Araki, M Uehara, K Kaneko, T Shirotani, M Todaka, S Ura, S Motoyoshi, K Matsumoto, N Miyamura, M Shichiri.   

Abstract

It has been suggested that bradykinin stimulates glucose uptake in experiments in vivo and in cultured cells. However, its mechanism has not yet been fully elucidated. In this study, the effects of bradykinin on the insulin signalling pathway were evaluated in isolated dog adipocytes. The bradykinin receptor binding study revealed that dog adipocytes possessed significant numbers of bradykinin receptors (Kd = 83 pmol/l, binding sites = 1.7 x 10(4) site/ cell). Reverse transcription-polymerase chain reaction amplification showed the mRNA specific for bradykinin B2 receptor in the adipocytes. Bradykinin alone did not increase 2-deoxyglucose uptake in adipocytes; however, in the presence of insulin (10(-7) mol/l) it significantly increased 2-deoxyglucose uptake in a dose-dependent manner. Bradykinin also enhanced insulin stimulated GLUT4 translocation from the intracellular fraction to the cell membrane, and insulin induced phosphorylation of the insulin receptor beta subunit and insulin receptor substrate-1 (IRS-1) without affecting the binding affinities or numbers of cell surface insulin receptors in dog adipocytes. The time-course of insulin stimulated phosphorylation of the insulin receptor beta subunit revealed that phosphorylation reached significantly higher levels at 10 min, and stayed at the higher levels until 120 min in the presence of bradykinin, suggesting that bradykinin delayed the dephosphorylation of the insulin receptor. It is concluded that bradykinin could potentiate insulin induced glucose uptake through GLUT4 translocation. This effect could be explained by the potency of bradykinin to upregulate the insulin receptor tyrosine kinase activity which stimulates phosphorylation of IRS-1, followed by GLUT4 translocation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8777990     DOI: 10.1007/bf00400672

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  42 in total

1.  Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene.

Authors:  E Araki; M A Lipes; M E Patti; J C Brüning; B Haag; R S Johnson; C R Kahn
Journal:  Nature       Date:  1994-11-10       Impact factor: 49.962

2.  Regulation of glucose transport by insulin, bombesin, and bradykinin in Swiss 3T3 fibroblasts: involvement of protein kinase C-dependent and -independent mechanisms.

Authors:  C Dettori; J Meldolesi
Journal:  Exp Cell Res       Date:  1989-05       Impact factor: 3.905

3.  Two bradykinin binding sites with picomolar affinities.

Authors:  D C Manning; R Vavrek; J M Stewart; S H Snyder
Journal:  J Pharmacol Exp Ther       Date:  1986-05       Impact factor: 4.030

4.  Bradykinin peptides in kidney, blood, and other tissues of the rat.

Authors:  D J Campbell; A Kladis; A M Duncan
Journal:  Hypertension       Date:  1993-02       Impact factor: 10.190

5.  Bradykinin and human forearm metabolism: inhibition of endogenous prostaglandin synthesis.

Authors:  G Dietze; M Wicklmayr; L Mayer; I Böttger; H von Funcke
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1978-03

6.  Bradykinin and bombesin rapidly stimulate tyrosine phosphorylation of a 120-kDa group of proteins in Swiss 3T3 cells.

Authors:  L M Leeb-Lundberg; X H Song
Journal:  J Biol Chem       Date:  1991-04-25       Impact factor: 5.157

7.  Antibodies to the alpha q subfamily of guanine nucleotide-binding regulatory protein alpha subunits attenuate activation of phosphatidylinositol 4,5-bisphosphate hydrolysis by hormones.

Authors:  S Gutowski; A Smrcka; L Nowak; D G Wu; M Simon; P C Sternweis
Journal:  J Biol Chem       Date:  1991-10-25       Impact factor: 5.157

8.  Bradykinin-stimulated inositol phosphate production in NG108-15 cells is mediated by a small population of binding sites which rapidly desensitize.

Authors:  D H Wolsing; J S Rosenbaum
Journal:  J Pharmacol Exp Ther       Date:  1991-05       Impact factor: 4.030

9.  Receptors for bradykinin in intact cultured human fibroblasts. Identification and characterization by direct binding study.

Authors:  A A Roscher; V C Manganiello; C L Jelsema; J Moss
Journal:  J Clin Invest       Date:  1983-08       Impact factor: 14.808

10.  Thiazolidine derivatives ameliorate high glucose-induced insulin resistance via the normalization of protein-tyrosine phosphatase activities.

Authors:  H Maegawa; R Ide; M Hasegawa; S Ugi; K Egawa; M Iwanishi; R Kikkawa; Y Shigeta; A Kashiwagi
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

View more
  9 in total

1.  Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways.

Authors:  Gang Yuan; Juanjuan Deng; Tao Wang; Chunxia Zhao; Xizheng Xu; Peihua Wang; James W Voltz; Matthew L Edin; Xiao Xiao; Lee Chao; Julie Chao; Xin A Zhang; Darryl C Zeldin; Dao Wen Wang
Journal:  Endocrinology       Date:  2007-02-01       Impact factor: 4.736

2.  Postexercise skeletal muscle glucose transport is normal in kininogen-deficient rats.

Authors:  George G Schweitzer; Gregory D Cartee
Journal:  Med Sci Sports Exerc       Date:  2011-07       Impact factor: 5.411

3.  The B2 receptor of bradykinin is not essential for the post-exercise increase in glucose uptake by insulin-stimulated mouse skeletal muscle.

Authors:  G G Schweitzer; C M Castorena; T Hamada; K Funai; E B Arias; G D Cartee
Journal:  Physiol Res       Date:  2011-03-14       Impact factor: 1.881

4.  Altered glucose homeostasis and hepatic function in obese mice deficient for both kinin receptor genes.

Authors:  Carlos C Barros; Anderson Haro; Fernanda J V P Russo; Ines Schadock; Sandro S Almeida; Rosane A Ribeiro; Emerielle C Vanzela; Valeria P Lanzoni; Flavio C Barros; Milton R Moraes; Marcelo A Mori; Reury F P Bacurau; Martin Wurtele; Antônio C Boschero; Everardo M Carneiro; Michael Bader; Joao B Pesquero; Ronaldo C Araujo
Journal:  PLoS One       Date:  2012-07-19       Impact factor: 3.240

5.  Kinin B1 receptor in adipocytes regulates glucose tolerance and predisposition to obesity.

Authors:  Marcelo A Mori; Vicência Micheline Sales; Fabiana Louise Motta; Raphael Gomes Fonseca; Natalia Alenina; Dioze Guadagnini; Ines Schadock; Elton Dias Silva; Hugo A M Torres; Edson Lucas dos Santos; Charlles Heldan Castro; Vânia D'Almeida; Sandra Andreotti; Amanda Baron Campaña; Rogério A L Sertié; Mario J A Saad; Fabio Bessa Lima; Michael Bader; João Bosco Pesquero
Journal:  PLoS One       Date:  2012-09-14       Impact factor: 3.240

6.  The Dual Role of Kinin/Kinin Receptors System in Alzheimer's Disease.

Authors:  Bingyuan Ji; Qinqin Wang; Qingjie Xue; Wenfu Li; Xuezhi Li; Yili Wu
Journal:  Front Mol Neurosci       Date:  2019-10-01       Impact factor: 5.639

7.  The bradykinin system in stress and anxiety in humans and mice.

Authors:  Ari Rouhiainen; Natalia Kulesskaya; Marie Mennesson; Zuzanna Misiewicz; Tessa Sipilä; Ewa Sokolowska; Kalevi Trontti; Lea Urpa; William McEntegart; Suvi Saarnio; Petri Hyytiä; Iiris Hovatta
Journal:  Sci Rep       Date:  2019-12-19       Impact factor: 4.379

8.  Kinin B1 and B2 receptor deficiency protects against obesity induced by a high-fat diet and improves glucose tolerance in mice.

Authors:  Rafael L Morais; Elton D Silva; Vicência M Sales; Rafael Filippelli-Silva; Marcelo A Mori; Michael Bader; João B Pesquero
Journal:  Diabetes Metab Syndr Obes       Date:  2015-08-26       Impact factor: 3.168

9.  Preclinical characterization of recombinant human tissue kallikrein-1 as a novel treatment for type 2 diabetes mellitus.

Authors:  Tadeusz Kolodka; Matthew L Charles; Arvind Raghavan; Ilian A Radichev; Christina Amatya; Jacob Ellefson; Alexei Y Savinov; Abhijeet Nag; Mark S Williams; Mark S Robbins
Journal:  PLoS One       Date:  2014-08-06       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.